United Therapeutics Expands Dry Powder Inhalation Collaboration with MannKind, Stock Rises 0.62% as $230M Volume Ranks 420th

On August 28, 2025, United Therapeutics (UTHR) rose 0.62%, with a trading volume of $0.23 billion, ranking 420th in market activity. The stock’s performance was influenced by a strategic development in its partnership with MannKind Corporation. United Therapeutics exercised its option to expand the 2018 collaboration agreement, aiming to develop a second dry powder inhalation therapy using MannKind’s Technosphere platform. This follows the 2022 FDA approval of Tyvaso DPI, the first FDA-cleared dry powder treatment for pulmonary hypertension.

Under the expanded agreement, MannKind will formulate a new investigational molecule, with United Therapeutics handling preclinical and clinical development. The company will receive an upfront $5 million payment, along with potential $35 million in development milestones and 10% royalties on future sales. The collaboration underscores United Therapeutics’ focus on expanding its pipeline for respiratory diseases, leveraging MannKind’s proprietary technology to address unmet medical needs in pulmonary hypertension and other conditions.

Query limit exceeded. The backtest results for the specified period could not be retrieved due to system constraints.